DNCB Test in Cancer Patients

L. Sadoff, M. Glovsky, A. Alenty, W. J. Catalona, P. T. Taylor, P. B. Chretien

Research output: Contribution to journalLetter

3 Citations (Scopus)

Abstract

To the Editor: The need for a standardized method of interpreting the DNCB skin test in patients with cancer was recently stressed by Catalona et al.1 Their unique approach in grading response is appealing, but may not represent an optimum method for detecting sensitization to DNCB. In testing over 50 patients with advanced cancer with DNCB, we used 1000 μg for initial sensitization, followed in two to three weeks with rechallenge doses of both 100 μg and 1000 μg. A majority of patients (75 per cent) reacted to the larger rechallenge dose, but very few (15 per cent) to a.

Original languageEnglish (US)
Pages (from-to)47-48
Number of pages2
JournalNew England Journal of Medicine
Volume287
Issue number1
DOIs
StatePublished - Jul 6 1972

Fingerprint

Dinitrochlorobenzene
Neoplasms
Skin Tests

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sadoff, L., Glovsky, M., Alenty, A., Catalona, W. J., Taylor, P. T., & Chretien, P. B. (1972). DNCB Test in Cancer Patients. New England Journal of Medicine, 287(1), 47-48. https://doi.org/10.1056/NEJM197207062870117
Sadoff, L. ; Glovsky, M. ; Alenty, A. ; Catalona, W. J. ; Taylor, P. T. ; Chretien, P. B. / DNCB Test in Cancer Patients. In: New England Journal of Medicine. 1972 ; Vol. 287, No. 1. pp. 47-48.
@article{e57f752216624914ad1ff332bf705858,
title = "DNCB Test in Cancer Patients",
abstract = "To the Editor: The need for a standardized method of interpreting the DNCB skin test in patients with cancer was recently stressed by Catalona et al.1 Their unique approach in grading response is appealing, but may not represent an optimum method for detecting sensitization to DNCB. In testing over 50 patients with advanced cancer with DNCB, we used 1000 μg for initial sensitization, followed in two to three weeks with rechallenge doses of both 100 μg and 1000 μg. A majority of patients (75 per cent) reacted to the larger rechallenge dose, but very few (15 per cent) to a.",
author = "L. Sadoff and M. Glovsky and A. Alenty and Catalona, {W. J.} and Taylor, {P. T.} and Chretien, {P. B.}",
year = "1972",
month = "7",
day = "6",
doi = "10.1056/NEJM197207062870117",
language = "English (US)",
volume = "287",
pages = "47--48",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "1",

}

Sadoff, L, Glovsky, M, Alenty, A, Catalona, WJ, Taylor, PT & Chretien, PB 1972, 'DNCB Test in Cancer Patients', New England Journal of Medicine, vol. 287, no. 1, pp. 47-48. https://doi.org/10.1056/NEJM197207062870117

DNCB Test in Cancer Patients. / Sadoff, L.; Glovsky, M.; Alenty, A.; Catalona, W. J.; Taylor, P. T.; Chretien, P. B.

In: New England Journal of Medicine, Vol. 287, No. 1, 06.07.1972, p. 47-48.

Research output: Contribution to journalLetter

TY - JOUR

T1 - DNCB Test in Cancer Patients

AU - Sadoff, L.

AU - Glovsky, M.

AU - Alenty, A.

AU - Catalona, W. J.

AU - Taylor, P. T.

AU - Chretien, P. B.

PY - 1972/7/6

Y1 - 1972/7/6

N2 - To the Editor: The need for a standardized method of interpreting the DNCB skin test in patients with cancer was recently stressed by Catalona et al.1 Their unique approach in grading response is appealing, but may not represent an optimum method for detecting sensitization to DNCB. In testing over 50 patients with advanced cancer with DNCB, we used 1000 μg for initial sensitization, followed in two to three weeks with rechallenge doses of both 100 μg and 1000 μg. A majority of patients (75 per cent) reacted to the larger rechallenge dose, but very few (15 per cent) to a.

AB - To the Editor: The need for a standardized method of interpreting the DNCB skin test in patients with cancer was recently stressed by Catalona et al.1 Their unique approach in grading response is appealing, but may not represent an optimum method for detecting sensitization to DNCB. In testing over 50 patients with advanced cancer with DNCB, we used 1000 μg for initial sensitization, followed in two to three weeks with rechallenge doses of both 100 μg and 1000 μg. A majority of patients (75 per cent) reacted to the larger rechallenge dose, but very few (15 per cent) to a.

UR - http://www.scopus.com/inward/record.url?scp=0015495964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015495964&partnerID=8YFLogxK

U2 - 10.1056/NEJM197207062870117

DO - 10.1056/NEJM197207062870117

M3 - Letter

C2 - 5029222

AN - SCOPUS:0015495964

VL - 287

SP - 47

EP - 48

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 1

ER -

Sadoff L, Glovsky M, Alenty A, Catalona WJ, Taylor PT, Chretien PB. DNCB Test in Cancer Patients. New England Journal of Medicine. 1972 Jul 6;287(1):47-48. https://doi.org/10.1056/NEJM197207062870117